Literature DB >> 24932958

Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set.

Kenneth R Gersing, John J Sheehan, Bruce Burchett, Ling Zhu, John A Bates, Ross A Baker, Iftekhar D Kalsekar.   

Abstract

OBJECTIVE: This study evaluated the relationship between patient characteristics and augmentation strategies for the treatment of major depressive disorder.
METHODS: This retrospective, cross-sectional study used data from a psychiatric electronic medical record database for patients with depression without psychosis or psychotic features who initiated augmentation therapy between January 2001 and June 2011. Medical records were evaluated to identify factors predicting use of specific augmentation agents, and a multivariate logistic regression model was used to assess clinical and demographic predictors of augmentation strategy.
RESULTS: Of 3,209 patients initiating augmentation therapy for depression, 75% received augmentation with an antidepressant combination and 11% received augmentation with second-generation antipsychotics. Baseline clinical severity (Clinical Global Impressions-Severity score) most strongly and consistently predicted augmentation with second-generation antipsychotics.
CONCLUSIONS: Treatment of patients in specialty settings with depression was often augmented with an antidepressant combination, whereas those with severe depression had an increased likelihood of augmentation with second-generation antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24932958     DOI: 10.1176/appi.ps.201300288

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  2 in total

1.  NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data.

Authors:  Rashmi Patel; Soon Nan Wee; Rajagopalan Ramaswamy; Simran Thadani; Jesisca Tandi; Ruchir Garg; Nathan Calvanese; Matthew Valko; A John Rush; Miguel E Rentería; Joydeep Sarkar; Scott H Kollins
Journal:  BMJ Open       Date:  2022-04-22       Impact factor: 3.006

2.  Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study.

Authors:  Roger S McIntyre; Emmanuelle Weiller
Journal:  Adv Ther       Date:  2015-05-13       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.